

### **REMARKS**

Restriction to one of the following groups was required under 35 USC 121 and 372:

- Group I claims 1-3, 8-10, 11-12, and 21, drawn to pharmaceutical compositions comprising an apolipoprotein L-1 or pharmaceutically active fragments thereof and methods for treatment and/or prevention of diseases induced in mammals by Trypanosoma which use said composition.
- Group II claims 1-3, 8-10, 11-12, and 21, drawn to pharmaceutical compositions comprising a polynucleotide which encodes an apolipoprotein L-1 or pharmaceutically active fragments thereof and host cells comprising said polynucleotide and methods for treatment and/or prevention of diseases induced in mammals by Trypanosoma which use said composition.
- Group III claims 1-3, 7, 8-10, 11-12, and 21, drawn to pharmaceutical composition comprising an inhibitor directed against an apolipoprotein L-1 or a pharmaceutically active fragments thereof wherein the inhibitor is an anti-idiotypic antibody or hyper variable portion thereof directed against an anti-apolipoprotein L-1 antibody and methods for treatment and/or prevention of diseases induced in mammals by Trypanosoma which use said composition.
- Group IV claims 1-6, 8-10, 11-13, 19, and 21, drawn to a pharmaceutical composition comprising an inhibitor directed against an apolipoprotein L-1 or a pharmaceutically active fragments thereof wherein the inhibitor is a trypanosoma serum resistance associated polypeptide, SRA or molecule which mimics the interaction between the polypeptide SRA and the apolipoprotein L-1 and methods for treatment and/or prevention of diseases induced in mammals by Trypanosoma which use said composition.
- Group V claims 14-16, 22, and 23, drawn to a non-human genetically modified mammal which expresses a polynucleotide which encodes an apolipoprotein L-1.
- Group VI claims 17, 18, and 24-29, drawn to a solid support comprising an inhibitor directed against an apolipoprotein L-1 and a method of recovering an apolipoprotein which uses said solid support.

**Application No.:** 10/523,466  
**Filing Date:** October 13, 2005

In response to this restriction requirement, Applicant elects group I, that is Claims 1-3, 8-10, 11-12, and 21.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 5, 2008

By: \_\_\_\_\_

  
Marina L. Cordery  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(310) 551-3450

4844379  
020408